| AiTan (rivoceranib) / HLB Bio Group |
ChiCTR-OPC-16007953: Clinical study of apatinib mesylate tablets in the treatment of refractory soft tissue sarcoma |
|
|
| Not yet recruiting | 4 | 30 | | Medical and nursing education for patients with soft tissue sarcoma | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Henry csco- Cancer Research Fund | Refractory soft tissue sarcoma | | | | |
ChiCTR-OPC-17010758: Mesylate apatinib combined with chemotherapy in the treatment of clinical study of osteosarcoma recurrence and metastasis |
|
|
| Recruiting | 4 | 40 | | Apatinib or apatinib + chemotherapy | Xijing Hospital affiliated to The Fourth Military Medical University; Xijing Hospital affiliated to The Fourth Military Medical University, 经费自筹 Self financing | osteosarcoma | | | | |
ChiCTR1800017424: Mesylate tablets of apatinib as first-line treatment of metastatic soft tissue sarcoma, randomized, crossover, multi center clinical study |
|
|
| Recruiting | 4 | 80 | | IFO+EPI regimen ;Pan apatinib scheme | General Hospital of Shenyang Military Area Command; General Hospital of Shenyang Military Area Command, Self-raising | metastatic soft tissue sarcoma | | | | |
ChiCTR1800016838: Clinical trial of secondary prevention of recombinant human thrombopoietin in the prevention of thrombocytopenia in advanced osteosarcoma with apatinib and docetaxel |
|
|
| Recruiting | 4 | 60 | | rhTPO | Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, funding | thrombocytopenia in advanced osteosarcoma | | | | |
ChiCTR1800016856: A prospective, randomized, controlled clinical trial of thalidomide against small molecule VEGFR oral targeted drug grade III-IV adverse reactions |
|
|
| Recruiting | 4 | 440 | | Apatinib + thalidomide 50~150mg/d, po.QN ;Apatinib ;Anlotinib Hydrochloride + thalidomide 50~150mg/d, po.QN ;Anlotinib ;Apatinib + thalidomide 50~150mg/d, po.QN ;Apatinib ;Anlotinib Hydrochloride + thalidomide 50~150mg/d, po.QN ;Anlotinib | Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Self-raised | Patients with advanced gastric cancer, lung cancer, and osteosarcoma taking apatinib or antatinib | | | | |
ChiCTR1800019995: A Clinical Study for the Efficacy and Safety of Apatinib Combined with Gemcitabine plus Paclitaxel in Patients with Advanced Hepatosarcomatoid Carcinoma |
|
|
| Not yet recruiting | 4 | 40 | | Apatinib 250mg, po, qd+Gemcitabine, iv, d1, d8+Paclitaxel, iv, d1 | First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Zhengzhou University, Self-pay | Advanced Hepatosarcomatoid Carcinoma | | | | |
ChiCTR-OIC-17013792: A Single arm, open, prospective study of Mesylate apatinib in the treatment of advanced bone and soft tissue sarcoma |
|
|
| Recruiting | 2 | 20 | | Apatinib | Beijing Jishuitan Hospital; Beijing Jishuitan Hospital, Optional subject | Bone and soft tissue sarcoma | | | | |
ChiCTR-OIC-17011964: The prospective, open-lable, single-arm, single-center clinical study of Apatinib mesylate non-first-line used in treating patients with recurrent/metastatic soft tissue sarcoma. |
|
|
| Not yet recruiting | 2 | 25 | | Continuous administration of apatinib 500mg/ days | The Affiliated Tumor Hospital of Guangxi Medical University; The Affiliated Tumor Hospital of Guangxi Medical University, Self-raised | recurrent/metastatic soft tissue sarcoma | | | | |
ChiCTR1800020407: Efficacy and safety of apapitatin mesylate in the treatment of metastatic gastrointestinal stromal tumor (GIST) with failed imatinib mesylate or sunitinib |
|
|
| Recruiting | 2 | 30 | | Apatinib 500mg qd | West China Hospital, Sichuan University; West China Hospital, Sichuan University, CSCO Funding | Gastrointestinal stromal tumor | | | | |
MAPAC, NCT04351308: Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma |
|
|
| Recruiting | 2 | 60 | RoW | MAPI chemotherapy, Apatinib Mesylate, Camrelizumab | Peking University People's Hospital, Chinese Sarcoma Study Group | Osteosarcoma, Survival, Chemotherapy Effect, Toxicity, Drug | 09/22 | 12/22 | | |
NCT05265793: Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma |
|
|
| Recruiting | 2 | 45 | RoW | Camrelizumab Combined With Apatinib, PD-1 immunotherapy and VEGFR-TKIs | Fudan University | PD-1 Immunotherapy, VEGFR-TKI, Sarcomatoid Carcinoma, Carcinosarcoma | 03/23 | 06/23 | | |
AIEO, NCT04824352: Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma |
|
|
| Suspended | 2 | 44 | RoW | apatinib, IE chemotherapy | Peking University People's Hospital, Peking University Shougang Hospital | Effect of Drug, Toxicity, Drug | 04/26 | 04/26 | | |
ChiCTR2000032649: A multicenter, open, single-arm, phase II study to evaluate the efficacy and safety of camrelizumab alone or in combination with Apatinib mesylate in patients with PD-L1-positive advanced lung sarcomatoid carcinoma |
|
|
| Not yet recruiting | 2 | 30 | | camrelizumab alone or in combination with Apatinib mesylate | The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd | lung sarcomatoid carcinoma | | | | |
NCT04012827: Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma |
|
|
| Recruiting | 2 | 108 | RoW | Apatinib Mesylate, doxorubicin, ifosfamide, Apatinib | Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd. | Soft Tissue Sarcoma | 06/23 | 12/23 | | |
OAIE, NCT05277480: Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma |
|
|
| Completed | 2 | 81 | RoW | Apatinib+IE, IE | Peking University People's Hospital, Jiangsu HengRui Medicine Co., Ltd. | Effect of Drug, Drug, Toxicity | 06/23 | 11/23 | | |
PROACH, NCT03742193: Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy |
|
|
| Active, not recruiting | 2 | 43 | RoW | Apatinib, VEGFR Inhibitor, GD regimen, Chemotherapy | Ruijin Hospital | Osteosarcoma, Pulmonary Metastases, Apatinib | 11/23 | 12/23 | | |
| Recruiting | 2 | 30 | RoW | Apatinib monotherapy, VEGFR inhibitor; Rivoceranib | Ruijin Hospital | Sarcoma | 10/26 | 09/27 | | |
ChiCTR2200062550: Phase II clinical study of apatinib tablet combined with chemotherapy in neoadjuvant therapy of adult osteosarcoma |
|
|
| Not yet recruiting | 2 | 24 | | Apatinib mesylate tablets combined with chemotherapy | Department of Orthopedics Oncology, Shanghai Changzheng Hospital; Shanghai Changzheng Hospital, Special funds | Osteosarcoma | | | | |
NCT05235100: Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma |
|
|
| Recruiting | 2 | 30 | RoW | Apatinib Mesylate | Chinese Academy of Medical Sciences | Sarcoma,Soft Tissue, Extremity, Trunk, Intensity-modulated Radiotherapy, Targetd Therapy, Major Wound Complications | 08/24 | 12/24 | | |
NCT06125171: Tucidinostat Plus Apatinib for Advanced Osteosarcoma |
|
|
| Not yet recruiting | 2 | 46 | NA | Tucidinostat, Apatinib | Wuhan Union Hospital, China | Osteosarcoma | 12/24 | 12/25 | | |
NCT05905887: Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor |
|
|
| Recruiting | 2 | 48 | RoW | Rivoceranib Mesylate, Paclitaxel | Asan Medical Center | Gastrointestinal Stromal Tumors | 08/26 | 12/26 | | |
ChiCTR2400086577: The efficacy and safety study of adebrelimab in combination with chemotherapy and apatinib for perioperative treatment of lung sarcomatoid carcinoma |
|
|
| Recruiting | 2 | 25 | | Pre-surgical neoadjuvant therapy phase1.Adebrelimab: 1200 mg IV, D1, Q3W, treatment for 2-4 cycles; 2. Apatinib: 250 mg, QD, half hour after meal, treatment for 2-4 cycles; 3. albumin paclitaxel: 260 mg/m2, D1, Q3W; 4. cisplatin: 70 mg/m2, D1, Q3W (no more than 130 mg)/carboplatin: 300-400 mg/m2, D1, Q3W.Chemotherapy may be given in split doses before and after surgery for a total of no more than 4 cycles of treatment.Surgery was performed within 6 weeks of the last neoadjuvant dose, and adjuvant therapy was administered within 6 weeks after surgery as assessed by the investigator.Post-surgical adjuvant therapy phase.Treatment regimen determined by the investigator (Adebrelimab1200 mg + apatinib 250 mg for up to 13 cycles is recommended for driver gene-negative patients; adjuvant treatment with TKIs is selected by the investigator for driver gene-positive patients). | Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Jiangsu Hengrui Medicine Co.,Ltd. | pulmonary sarcomatoid carcinoma | | | | |
ChiCTR2100049548: Open phase I / IIA trial of vg161 monotherapy or combined with apatinib in the treatment of advanced osteosarcoma, Ewing's sarcoma, chordoma and chondrosarcoma |
|
|
| Not yet recruiting | 1/2 | 32 | | VG161 ;VG161+apatinib | Shanghai Changzheng Hospital; Shanghai Changzheng Hospital, No | Advanced osteosarcoma, Ewing's sarcoma, chordoma and chondrosarcoma | | | | |
NCT04074564: MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma |
|
|
| Recruiting | 1 | 60 | RoW | MASCT-I, Camrelizumab,Apatinib | HRYZ Biotech Co. | Sarcoma | 08/24 | 12/24 | | |
ChiCTR2300075156: Phase I clinical study on tolerability, safety, and efficacy of Dalpiciclib combined with Apatinib in the treatment of patients with advanced or metastatic sarcoma |
|
|
| Not yet recruiting | 1 | 9 | | Dalpiciclib 100mg once daily oral d1-21+Apatinib 250mg once daily oral d1-28, every 28 days as one cycle; ; Dalpiciclib 100mg once daily oral d1-21+Apatinib 500mg once daily oral d1-28, every 28 days as one cycle; ; Dalpiciclib 150mg once daily oral d1-21+Apatinib 500mg once daily oral d1-28, every 28 days as one cycle; | Peking University Third Hospital; Peking University Third Hospital, Self-fding | Sarcoma | | | | |
ChiCTR-INR-17013663: The clinical study on the safety and effectiveness of Apatinib Mesylate in locally advanced head and neck soft tissue sarcoma with the induction chemotherapy treatment |
|
|
| Recruiting | N/A | 40 | | induction chemotherapy-Apatinib Mesylat-surgery-radiotherapy-adjuvant chemotherapy ;induction chemotherapy-surgery-radiotherapy-adjuvant chemotherapy | Beijing TongRen Hospital, Capital Medicine University; Beijing TongRen Hospital, Capital Medicine University, Beijing TongRen Hospital, Capital Medicine University | head and neck soft tissue sarcoma | | | | |
ChiCTR1900025515: To explore the efficacy of MASCT-I combined with PD1 antibody and apatinib mesylate in the treatment of advanced osteosarcoma and soft tissue sarcoma. |
|
|
| Not yet recruiting | N/A | 20 | | MASCT-I A+PD1 antibody+Apatinib ;MASCT-I B+PD1 antibody+Apatinib | Shanghai Sixth People's Hospital; HRYZ (ShenZhen) Biotech Co., HRYZ (ShenZhen) Biotech Co. | Advanced Osteosarcoma and Soft Tissue Sarcoma | | | | |
ChiCTR-OOC-17013435: Clinical Research of radiotherapy combined with apatinib mesylate tablets in the treatment of residual, recurrent and metastatic sarcoma |
|
|
| Recruiting | N/A | 50 | | radiotherapy combined with apatinib | The First Hospital of Jilin University; The First Hospital of Jilin University, Self-financing | sarcoma | | | | |
ChiCTR2100054019: Clinical value and exploration of Apatinib combined with SHR-1210 in perioperative adjuvant treatment of retroperitoneal sarcomas |
|
|
| Recruiting | N/A | 93 | | Apatinib combined with SHR-1210( Before the surgery) ;surgery | Beijing Cancer Hospital / Peking University Cancer Hospital; Peking University Cancer Hospital, Capital Health Development of Special Funding Support | Retroperitoneal Sarcoma | | | | |
NCT05751733: Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST |
|
|
| Recruiting | N/A | 258 | RoW | Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib | Xiangya Hospital of Central South University, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Gastrointestinal Stromal Tumors | 01/26 | 01/27 | | |
